Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial

BACKGROUND: Adding anti-angiogenics to neoadjuvant chemotherapy for localized gastric cancer is recognized as a promising strategy, but its clinical value remains to be defined. METHODS: This single-center, single-arm, phase 2 trial included patients with locally advanced (cT3/4aN+M0) adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Zhaoqing, Wang, Yan, Yu, Yiyi, Cui, Yuehong, Liang, Liang, Xu, Chen, Shen, Zhenbin, Shen, Kuntang, Wang, Xuefei, Liu, Tianshu, Sun, Yihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985371/
https://www.ncbi.nlm.nih.gov/pubmed/35382819
http://dx.doi.org/10.1186/s12916-022-02309-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985371/
https://www.ncbi.nlm.nih.gov/pubmed/35382819
http://dx.doi.org/10.1186/s12916-022-02309-0

Ejemplares similares